Named on the TIME100 Health 2025 list, Xia was recognized for her leadership in advancing innovative biopharmaceutical development, particularly antibody-based cancer therapies. As founder and CEO of Akeso, she has driven the development of novel drugs such as ivonescimab, helping accelerate global clinical research and expand access to cutting-edge treatments across international markets.

(Photo: STAT)